이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NextCure 관리

관리 기준 확인 3/4

NextCure's CEO는 Michael Richman, Oct2015 에 임명되었습니다 의 임기는 8.67 년입니다. 총 연간 보상은 $ 1.04M, 54.7% 로 구성됩니다. 54.7% 급여 및 45.3% 보너스(회사 주식 및 옵션 포함). 는 $ 536.35K 가치에 해당하는 회사 주식의 1.45% 직접 소유합니다. 536.35K. 경영진과 이사회의 평균 재임 기간은 각각 3.4 년과 5.2 년입니다.

주요 정보

Michael Richman

최고 경영자

US$1.0m

총 보상

CEO 급여 비율	54.7%
CEO 임기	8.8yrs
CEO 소유권	1.5%
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

May 10

NextCure EPS misses by $0.01

May 06

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Feb 12

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

Jan 08

NextCure provides update on NC318 clinical program

Dec 17

CEO 보상 분석

Michael Richman 의 보수는 NextCure 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$64m
Dec 31 2023	US$1m	US$572k	-US$63m
Sep 30 2023	n/a	n/a	-US$66m
Jun 30 2023	n/a	n/a	-US$70m
Mar 31 2023	n/a	n/a	-US$70m
Dec 31 2022	US$2m	US$549k	-US$75m
Sep 30 2022	n/a	n/a	-US$74m
Jun 30 2022	n/a	n/a	-US$73m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$3m	US$529k	-US$69m
Sep 30 2021	n/a	n/a	-US$68m
Jun 30 2021	n/a	n/a	-US$66m
Mar 31 2021	n/a	n/a	-US$63m
Dec 31 2020	US$6m	US$491k	-US$37m
Sep 30 2020	n/a	n/a	-US$32m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$626k	US$419k	-US$34m
Sep 30 2019	n/a	n/a	-US$30m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$24m
Dec 31 2018	US$3m	US$383k	-US$23m

보상 대 시장: Michael 의 총 보상 ($USD 1.04M )은 US 시장( $USD 683.56K ).

보상과 수익: Michael 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Michael Richman (63 yo)

8.8yrs

테뉴어

US$1,044,627

보상

Mr. Michael S. Richman, MSBA, Co-founded NextCure, Inc. since 2015 and has been its Chief Executive Officer, President & Director since July 2015. Mr. Richman served as the Chief Executive Officer and Pres...

리더십 팀

이름	위치	테뉴어	보상	소유권
Michael Richman	Co-Founder	8.8yrs	US$1.04m	1.45% $ 637.9k
Solomon Langermann	Chief Scientific Officer	5.6yrs	US$681.59k	0.13% $ 58.6k
Han Myint	Chief Medical Officer	3.5yrs	US$697.93k	0% $ 0
Lieping Chen	Co-Founder & Chairman of Scientific Advisory Board	9.5yrs	데이터 없음	데이터 없음
Steven Cobourn	Chief Financial Officer	6.5yrs	US$1.01m	데이터 없음
Timothy Mayer	Chief Operating Officer	4.8yrs	데이터 없음	데이터 없음
Kevin Shaw	Senior VP & General Counsel	2.2yrs	데이터 없음	데이터 없음
Stacy Rollinger	Vice President of Human Resources	less than a year	데이터 없음	데이터 없음
Sourav Kundu	Senior Vice President of Development & Manufacturing	3yrs	데이터 없음	데이터 없음
Sebastien Maloveste	Senior Vice President of Business Development	less than a year	데이터 없음	데이터 없음
Udayan Guha	Senior Vice President of Clinical & Translational Development	less than a year	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 관리: NXTC 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michael Richman	Co-Founder	8.8yrs	US$1.04m	1.45% $ 637.9k
Lieping Chen	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Elaine Jones	Independent Director	8.6yrs	US$67.47k	0% $ 0
Mario Sznol	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
David Kabakoff	Independent Chairman of the Board	8.6yrs	US$93.16k	0.22% $ 97.7k
Stephen Webster	Independent Director	5.3yrs	US$71.66k	0% $ 0
Ellen Feigal	Independent Director	2.8yrs	US$61.66k	0% $ 0
Stephen Miller	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
John Houston	Independent Director	3.8yrs	US$61.66k	0% $ 0
Weiping Zou	Member of Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음
Ursula Matulonis	Member of Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음
Anne Borgman-Hagey	Independent Director	2.8yrs	US$60.66k	0% $ 0

3.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: NXTC 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.

NextCure 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

High number of new directors

Recent updates

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

New major risk - Revenue and earnings growth

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Nextcure, Inc. Provides Year-End Clinical Pipeline Updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605

NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Price target decreased by 25% to US$4.33

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

Price target decreased by 25% to US$4.33

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

Price target increased to US$6.67

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Price target decreased to US$5.80

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Price target decreased to US$6.25

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Price target increased to US$14.14

NextCure GAAP EPS of -$0.59

NextCure, Inc. Presents NC410 Data at the Extracellular Matrix Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

High number of new directors

Now 23% undervalued after recent price drop

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

NextCure, Inc. and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

Price target decreased to US$16.75

High number of new directors

Independent Director Xiaoxing Xu has left the company

NextCure: Large Upside With Downside Protected By Cash Pile

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell 2500 Growth Index

Nextcure and Collaborators Publish Preclinical Data on Novel Immunomedicine Nc410

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

NextCure EPS misses by $0.01

Independent Director has left the company

Full year 2020 earnings released: US$1.33 loss per share (vs US$2.15 loss in FY 2019)

Revenue behind estimates

NextCure, Inc. Announces Resignation of Briggs Morrison from the Board of Directors, Effective April 1, 2021

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

New 90-day high: US$13.64

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Nextcure, Inc

NextCure, Inc. Announces the Appointment of Han Myint as Chief Medical Officer

New 90-day high: US$13.07

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

NextCure, Inc. Provides Updates on NC318 Clinical Program

NextCure provides update on NC318 clinical program

Rosen Reminds Nextcure, Inc. Investors of Important November 20 Deadline in Securities Class Action

Earnings beat expectations

New 90-day high: US$11.65

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Against Nextcure Inc

Block & Leviton LLP Reminds Investors of Nextcure, Inc. for Violations of the Federal Securities Laws

Nextcure, Inc. Announces Resignation of Kevin N. Heller from Chief Medical Officer

Scott+Scott Attorneys At Law LLP Files Securities Class Action Against NextCure Inc

First half earnings released

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Value Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from S&P Biotechnology Select Industry Index